With more than 40 years of experience in projects
for BigPharma, BioTech, Academic Institutions and CROs.
COMPANY INFORMATION | NEU-ULM | 23.03.2020
Since the late 2019 onset of COVID-19 (Coronavirus) in Asia, NUVISAN's management has been closely following the spread of the virus and the development of the disease as well as the measures adopted by local governments aimed to contain the further spread of the virus, assessing their potential impact and anticipated precautionary measures.
↓ read complete announcement / PDF / 438 KB
Connected services and support along the value chain
from research up to completions of phase II
NUVISAN provides all services from one single source
according from API Synthesis, Formulation Development
to Non-Clinical, Early Clinical, Pharmaceutical
as well as Bioanalytical Lab Services.
PRESS RELEASE | NEU-ULM | BERLIN | 11.02.2020
Neu-Ulm/ Berlin, February 10, 2020 – NUVISAN has agreed with Bayer to integrate large parts of Bayer’s Berlin-based small molecule research unit and complements hereby its services in the field of preclinical research.
↓ read complete Press Release / PDF / 428 KB
Years of experience
Sites across Europe
High educated motivated people
NUVISAN Pharma Services is a fully integrated Contract Research Organization and pharmaceutical service provider with an with a 40-years track record of serving clients’ needs in early and clinical development.
NUVISAN started operations as the privately owned contract research institute, LAB in 1979 and has been performing clinical pharmacological and pharmacokinetic studies, ever since.
Our philosophy is to offer all relevant GxP Services from one source to support clients from discovery to the entry in clinical development.